Truist lowered the firm's price target on Greif to $78 from $79 and keeps a Hold rating on the shares after its Q1 results. The impact of the Middle East conflict is tempering the company's guidance, though the management's structural cost actions position Greif for recovery, the analyst tells investors in a research note.
